OTTAWA, ON , May 20, 2026 /CNW/ - CSL Canada is proud to announce the first Canadian patient has received HEMGENIX ® (etranacogene dezaparvovec), a one-time hemophilia B gene therapy, at London...
New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018
Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. CSL Limited (OTC: CSLLY) is a global biopharma...
- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit ...
Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0 ™ principles with sustainable design to transform plasma manufacturing
SUMMIT, N.J. , Oct. 21, 2025 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing test-confirmed...
In a report released on October 13, Steven Wheen from Jarden maintained a Buy rating on CSL, with a price target of A$298.13. The company’s shares closed yesterday at $131.65.Elevate Your Investing Strategy:...
Bell Potter analyst Thomas Wakim maintained a Hold rating on CSL today and set a price target of A$230.00. The company’s shares closed yesterday at $131.65.Elevate Your Investing Strategy: Take advantage...
UBS analyst Marcus Curley maintained a Buy rating on CSL today and set a price target of A$300.00. The company’s shares closed today at $131.65.Elevate Your Investing Strategy: Take advantage of TipRanks...